W

ASHINGTON — The federal government is spending more money on brand-name drugs for seniors in the Medicare Part D program, even as the number of prescriptions falls, a government watchdog report released Monday concluded.

The analysis, conducted by the Department of Health and Human Services Office of Inspector General, landed in Washington amid talks of radical changes to the Part D program, which typically covers drugs dispensed at a pharmacy.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Supposed to happen that way. No other choices. Every drug even if it is not an orphan drug will be priced high to maintain the “C” suit lifestyle.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy